145 related articles for article (PubMed ID: 24035338)
1. Discovery of 2,8-diazaspiro[4.5]decane-based trisubstituted urea derivatives as highly potent soluble epoxide hydrolase inhibitors and orally active drug candidates for treating hypertension.
Kato Y; Fuchi N; Saburi H; Nishimura Y; Watanabe A; Yagi M; Nakadera Y; Higashi E; Yamada M; Aoki T
Bioorg Med Chem Lett; 2013 Nov; 23(21):5975-9. PubMed ID: 24035338
[TBL] [Abstract][Full Text] [Related]
2. Discovery of 1-oxa-4,9-diazaspiro[5.5]undecane-based trisubstituted urea derivatives as highly potent soluble epoxide hydrolase inhibitors and orally active drug candidates for treating of chronic kidney diseases.
Kato Y; Fuchi N; Nishimura Y; Watanabe A; Yagi M; Nakadera Y; Higashi E; Yamada M; Aoki T; Kigoshi H
Bioorg Med Chem Lett; 2014 Jan; 24(2):565-70. PubMed ID: 24373724
[TBL] [Abstract][Full Text] [Related]
3. Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.
Shen HC; Ding FX; Deng Q; Xu S; Chen HS; Tong X; Tong V; Zhang X; Chen Y; Zhou G; Pai LY; Alonso-Galicia M; Zhang B; Roy S; Tata JR; Berger JP; Colletti SL
Bioorg Med Chem Lett; 2009 Sep; 19(18):5314-20. PubMed ID: 19682899
[TBL] [Abstract][Full Text] [Related]
4. Discovery of spirocyclic secondary amine-derived tertiary ureas as highly potent, selective and bioavailable soluble epoxide hydrolase inhibitors.
Shen HC; Ding FX; Wang S; Xu S; Chen HS; Tong X; Tong V; Mitra K; Kumar S; Zhang X; Chen Y; Zhou G; Pai LY; Alonso-Galicia M; Chen X; Zhang B; Tata JR; Berger JP; Colletti SL
Bioorg Med Chem Lett; 2009 Jul; 19(13):3398-404. PubMed ID: 19481932
[TBL] [Abstract][Full Text] [Related]
5. Structure-based optimization of cyclopropyl urea derivatives as potent soluble epoxide hydrolase inhibitors for potential decrease of renal injury without hypotensive action.
Takai K; Nakajima T; Takanashi Y; Sone T; Nariai T; Chiyo N; Nakatani S; Ishikawa C; Yamaguchi N; Fujita K; Yamada K
Bioorg Med Chem; 2014 Mar; 22(5):1548-57. PubMed ID: 24530032
[TBL] [Abstract][Full Text] [Related]
6. Three-dimensional rational approach to the discovery of potent substituted cyclopropyl urea soluble epoxide hydrolase inhibitors.
Takai K; Chiyo N; Nakajima T; Nariai T; Ishikawa C; Nakatani S; Ikeno A; Yamamoto S; Sone T
Bioorg Med Chem Lett; 2015 Apr; 25(8):1705-1708. PubMed ID: 25800114
[TBL] [Abstract][Full Text] [Related]
7. Oral delivery of 1,3-dicyclohexylurea nanosuspension enhances exposure and lowers blood pressure in hypertensive rats.
Ghosh S; Chiang PC; Wahlstrom JL; Fujiwara H; Selbo JG; Roberds SL
Basic Clin Pharmacol Toxicol; 2008 May; 102(5):453-8. PubMed ID: 18312493
[TBL] [Abstract][Full Text] [Related]
8. 1-(1-acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea (AR9281) as a potent, selective, and orally available soluble epoxide hydrolase inhibitor with efficacy in rodent models of hypertension and dysglycemia.
Anandan SK; Webb HK; Chen D; Wang YX; Aavula BR; Cases S; Cheng Y; Do ZN; Mehra U; Tran V; Vincelette J; Waszczuk J; White K; Wong KR; Zhang LN; Jones PD; Hammock BD; Patel DV; Whitcomb R; MacIntyre DE; Sabry J; Gless R
Bioorg Med Chem Lett; 2011 Feb; 21(3):983-8. PubMed ID: 21211973
[TBL] [Abstract][Full Text] [Related]
9. Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage.
Zhao X; Yamamoto T; Newman JW; Kim IH; Watanabe T; Hammock BD; Stewart J; Pollock JS; Pollock DM; Imig JD
J Am Soc Nephrol; 2004 May; 15(5):1244-53. PubMed ID: 15100364
[TBL] [Abstract][Full Text] [Related]
10. Role of haem oxygenase in the renoprotective effects of soluble epoxide hydrolase inhibition in diabetic spontaneously hypertensive rats.
Elmarakby AA; Faulkner J; Pye C; Rouch K; Alhashim A; Maddipati KR; Baban B
Clin Sci (Lond); 2013 Oct; 125(7):349-59. PubMed ID: 23611540
[TBL] [Abstract][Full Text] [Related]
11. Novel mechanism of brain soluble epoxide hydrolase-mediated blood pressure regulation in the spontaneously hypertensive rat.
Sellers KW; Sun C; Diez-Freire C; Waki H; Morisseau C; Falck JR; Hammock BD; Paton JF; Raizada MK
FASEB J; 2005 Apr; 19(6):626-8. PubMed ID: 15659536
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and SAR of conformationally restricted inhibitors of soluble epoxide hydrolase.
Jones PD; Tsai HJ; Do ZN; Morisseau C; Hammock BD
Bioorg Med Chem Lett; 2006 Oct; 16(19):5212-6. PubMed ID: 16870439
[TBL] [Abstract][Full Text] [Related]
13. Discovery of memantyl urea derivatives as potent soluble epoxide hydrolase inhibitors against lipopolysaccharide-induced sepsis.
Du F; Sun W; Morisseau C; Hammock BD; Bao X; Liu Q; Wang C; Zhang T; Yang H; Zhou J; Xiao W; Liu Z; Chen G
Eur J Med Chem; 2021 Nov; 223():113678. PubMed ID: 34218083
[TBL] [Abstract][Full Text] [Related]
14. Insight into the binding modes and inhibition mechanisms of adamantyl-based 1,3-disubstituted urea inhibitors in the active site of the human soluble epoxide hydrolase.
Chen H; Zhang Y; Ye C; Feng TT; Han JG
J Biomol Struct Dyn; 2014; 32(8):1231-47. PubMed ID: 23815795
[TBL] [Abstract][Full Text] [Related]
15. Differential cardiotoxicity in response to chronic doxorubicin treatment in male spontaneous hypertension-heart failure (SHHF), spontaneously hypertensive (SHR), and Wistar Kyoto (WKY) rats.
Sharkey LC; Radin MJ; Heller L; Rogers LK; Tobias A; Matise I; Wang Q; Apple FS; McCune SA
Toxicol Appl Pharmacol; 2013 Nov; 273(1):47-57. PubMed ID: 23993975
[TBL] [Abstract][Full Text] [Related]
16. Soluble epoxide hydrolase is a main effector of angiotensin II-induced hypertension.
Jung O; Brandes RP; Kim IH; Schweda F; Schmidt R; Hammock BD; Busse R; Fleming I
Hypertension; 2005 Apr; 45(4):759-65. PubMed ID: 15699457
[TBL] [Abstract][Full Text] [Related]
17. Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement.
Shen HC; Ding FX; Wang S; Deng Q; Zhang X; Chen Y; Zhou G; Xu S; Chen HS; Tong X; Tong V; Mitra K; Kumar S; Tsai C; Stevenson AS; Pai LY; Alonso-Galicia M; Chen X; Soisson SM; Roy S; Zhang B; Tata JR; Berger JP; Colletti SL
J Med Chem; 2009 Aug; 52(16):5009-12. PubMed ID: 19645482
[TBL] [Abstract][Full Text] [Related]
18. Discovery of polar spirocyclic orally bioavailable urea inhibitors of soluble epoxide hydrolase.
Lukin A; Kramer J; Hartmann M; Weizel L; Hernandez-Olmos V; Falahati K; Burghardt I; Kalinchenkova N; Bagnyukova D; Zhurilo N; Rautio J; Forsberg M; Ihalainen J; Auriola S; Leppänen J; Konstantinov I; Pogoryelov D; Proschak E; Dar'in D; Krasavin M
Bioorg Chem; 2018 Oct; 80():655-667. PubMed ID: 30059891
[TBL] [Abstract][Full Text] [Related]
19. Renal mechanisms contributing to the antihypertensive action of soluble epoxide hydrolase inhibition in Ren-2 transgenic rats with inducible hypertension.
Honetschlägerová Z; Husková Z; Vaňourková Z; Sporková A; Kramer HJ; Hwang SH; Tsai HJ; Hammock BD; Imig JD; Červenka L; Kopkan L
J Physiol; 2011 Jan; 589(Pt 1):207-19. PubMed ID: 21078594
[TBL] [Abstract][Full Text] [Related]
20. Investigation of the binding mode of 1, 3, 4-oxadiazole derivatives as amide-based inhibitors for soluble epoxide hydrolase (sEH) by molecular docking and MM-GBSA.
Karami L; Saboury AA; Rezaee E; Tabatabai SA
Eur Biophys J; 2017 Jul; 46(5):445-459. PubMed ID: 27928588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
